CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®

  • Posted by: BIOCON

Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: BIOCON

Biocon Foundation, in partnership with BeST Cluster and NCBS, onboards first BioWISE cohort of Postgraduate Women Students

  • Posted by: BIOCON

Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

  • Posted by: BIOCON

Biocon obtains approval for weight management drug, Liraglutide, in the United States

  • Posted by: BIOCON

Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr

  • Posted by: BIOCON

Fitch Ratings Revises Biocon Biologics Outlook from ‘Stable’ to ‘Positive’

  • Posted by: BIOCON

S&P Global Upgrades Biocon Biologics Credit Rating To ‘BB+’ Revises Outlook to “Stable”

  • Posted by: BIOCON

Biocon Limited Concludes Rs 4,150 Crore (~USD 460 million) Equity Fundraise through a Ǫualified Institutions Placement (ǪIP)

  • Posted by: BIOCON

Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference

  • Posted by: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>